Exato Technologies Ltd
544626Exato Technologies Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 98th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (33 weeks in) while the P/E sits at the 98th percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −24.2% year on year, and 3% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Exato Technologies Ltd trades at ₹586, in a confirmed uptrend and 33 weeks into that stage. That is +54.9% against its own 200-day average. It sits at 100% of a 52-week range of ₹354 to ₹586. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 33 of stage 2, confirmed. At ₹586 it trades +54.9% versus its 200-day average and sits at 100% of its 52-week range (₹354–₹586).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +65% while the NIFTY 500 moved +4% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Exato Technologies Ltd trades at 36.6× P/E, about the priciest it has ever traded. Its long-run median P/E is 0.1×, measured across 0.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.6× is about the priciest it has ever traded, against a long-run median of 0.1× measured over 0.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Exato Technologies Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +35.5% | +32.0% | — | — |
| Profit | +60.0% | +47.4% | — | — |
| EPS | −99.8% | −84.2% | — | — |
4-Factor Sector Score
52.7/100 — rank 55 of 63 in IT - Software · 33% evidence confidence · provisional, ranked below fully-evidenced peers
Exato Technologies Ltd scores 52.7 out of 100 against the 63 companies it is compared with in IT - Software, ranking 55. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.1 + 16.1 + 9.5 + 10 = 52.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Exato Technologies Ltd reported ₹61.1 Cr of revenue in the Mar 26 quarter, +4.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 3 years it has compounded at 32.0% a year. The last full year, FY26, came in at ₹168 Cr. The last four reported quarters add to ₹198 Cr.
FY26 revenue came in at ₹168 Cr (+35.5% on the year), capping 3 years at 32.0% compound. The latest quarter (Mar 26) printed ₹61.1 Cr, +4.0% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.2% growth against the decade's 32.0% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Exato Technologies Ltd's operating margin is 10.4% in the Mar 26 quarter, −3.9 percentage points against the same quarter a year ago. Across the last four quarters the operating margin has moved −2.7 percentage points. Across 4 fiscal years the operating margin has ranged 7.0% to 14.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 10.4%, −3.9 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 7.0%–14.0%.
🚨 Why the margin moved: operating margin went −2.7 pp year on year while gross margin went −7.3 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Exato Technologies Ltd earned ₹4.2 Cr of net profit in the Mar 26 quarter, −24.2% year on year. Full-year FY26 profit was ₹16.0 Cr. The 3-year compound rate is 47.4%. That is 6.9% of the quarter's revenue. The same quarter a year earlier earned ₹2.5 Cr.
Mar 26 profit was ₹4.2 Cr, −24.2% year on year. On the full year, FY26 printed ₹16.0 Cr (+60.0%), and the 3-year compound rate is 47.4%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 3% of Exato Technologies Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹2.0 Cr of operating cash against ₹16.0 Cr of profit. After ₹13.0 Cr of capital spending, ₹−11.0 Cr was left as free cash.
FY26: operating cash of ₹2.0 Cr against reported profit of ₹16.0 Cr, leaving free cash of ₹−11.0 Cr after ₹13.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 3% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 3%: the cash cycle stretched 65 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 65 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Exato Technologies Ltd's cash conversion cycle runs 80 days in FY26, up from 15 days in FY23. Capital spending ran ₹32.0 Cr over the last 3 years. At FY26 sales of ₹168 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹37.0 Cr sits inside the business at any moment.
FY26: debtors at 93 days, inventory at 11 days — roughly 0.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 80 days, looser than FY23's 15.
The full loop: cash goes out to suppliers and production on day 0; stock waits 11 days to sell; customers pay about 93 days after that; and suppliers themselves are paid at 24 days — netting out to the 80-day cycle.
In money terms: at FY26 sales of ₹168 Cr, each day of the cycle holds about ₹0.5 Cr — so the 80-day loop keeps roughly ₹37.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹32.0 Cr over the last 3 fiscal years against ₹2.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Exato Technologies Ltd earns a ROCE of 27% in FY26. That is up from a trough of 25% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.5% net margin on 1.37× asset turns.
FY26 ROCE is 27%, recovered from a FY24 trough of 25% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.5% net margin × 1.37× asset turns × 1.40× balance-sheet leverage ≈ 18.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Exato Technologies Ltd carries ₹21.0 Cr of borrowings against ₹88.0 Cr of equity in FY26, a debt-to-equity of 0.24. Operating profit covers the interest bill 12×. Over 3 years borrowings went from ₹6.0 Cr to ₹21.0 Cr. Capital spending ran ₹32.0 Cr across the last 3 of those years.
FY26: borrowings of ₹21.0 Cr against equity of ₹88.0 Cr — a debt-to-equity of 0.24. Operating profit covers the interest bill 12×. Over 3 years borrowings went from ₹6.0 Cr to ₹21.0 Cr while capital spending ran ₹32.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Exato Technologies Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Exato Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 75.9/100Favorable setup100% evidence | BREAKING OUT | 30.3/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.6/25 ROCE 23.5% · OPM 19% 100% evidence | 12.6/20 P/E 39.8× · PEG 0.57 100% evidence | 17.4/20 RS sector 7.8% · RS bench 10.4% · 1Y 1.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.3 + 15.6 + 12.6 + 17.4 = 75.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 71.3/100Favorable setup93% evidence | LEADER | 30.6/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 16.9/25 ROCE 28.9% · OPM 22% 100% evidence | 10.2/20 P/E 61.4× · PEG 1.11 65% evidence | 13.6/20 RS sector 54.7% · RS bench 61.9% · 1Y 157%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.6 + 16.9 + 10.2 + 13.6 = 71.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3NINtec Systems LtdNINSYS | 70.8/100Favorable setup76% evidence | LEADER | 20.8/35 Revenue 21.7% · PAT 21.6% · OPM change 8.1 pp 83% evidence | 21.9/25 ROCE 55% · OPM 30.1% 95% evidence | 9.2/20 P/E 45.4× · PEG — 15% evidence | 18.9/20 RS sector 53.9% · RS bench 58.6% · 1Y 84.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 21.9 + 9.2 + 18.9 = 70.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4InfoBeans Technologies LtdINFOBEAN | 67.4/100Favorable setup81% evidence | ASLEEP | 27.0/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.8/25 ROCE 29.2% · OPM 21% 95% evidence | 9.5/20 P/E 19× · PEG — 50% evidence | 14.1/20 RS sector 17.4% · RS bench -0.7% · 1Y 18.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 27 + 16.8 + 9.5 + 14.1 = 67.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Sasken Technologies LtdSASKEN | 65.9/100Favorable setup100% evidence | LEADER | 30.8/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 7.7/25 ROCE 9.9% · OPM 9% 100% evidence | 9.6/20 P/E 37.3× · PEG 0.68 100% evidence | 17.8/20 RS sector 15.4% · RS bench 19.1% · 1Y 23.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 7.7 + 9.6 + 17.8 = 65.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Sahana Systems LtdSAHANA | 65.3/100Favorable setup70% evidence | BASING | 21.8/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.4/25 ROCE 39.8% · OPM 29% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 9.7/20 RS sector -14.3% · RS bench 3.2% · 1Y -35.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 19.4 + 14.4 + 9.7 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Cigniti Technologies LtdCIGNITITEC | 64.3/100Mixed-positive evidence79% evidence | 23.4/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.1/25 ROCE 34.1% · OPM 18% 75% evidence | 16.1/20 P/E 11.4× · PEG 0.61 100% evidence | 8.7/20 RS sector -9.5% · RS bench -15% · 1Y -20.5%0 of 1 week ahead to 2026-05-17 100% evidence | |
| Exact sum: 23.4 + 16.1 + 16.1 + 8.7 = 64.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Hypersoft Technologies Ltd539724 | 63.2/100Mixed-positive evidence61% evidence | LEADER | 25.7/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 12.0/25 ROCE 20.6% · OPM 14% 76% evidence | 8.6/20 P/E 441× · PEG — 15% evidence | 16.9/20 RS sector 81.1% · RS bench 88.7% · 1Y 282.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 25.7 + 12 + 8.6 + 16.9 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tech Mahindra LtdTECHM | 63.0/100Mixed-positive evidence94% evidence | TURNING | 20.8/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.1/25 ROCE 23.1% · OPM 17% 100% evidence | 10.8/20 P/E 30.4× · PEG 0.76 100% evidence | 15.3/20 RS sector 14.8% · RS bench 9.3% · 1Y 13%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20.8 + 16.1 + 10.8 + 15.3 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10ASM Technologies Ltd526433 | 62.9/100Mixed-positive evidence65% evidence | TURNING | 23.7/35 Revenue 82.1% · PAT 100% · OPM change -4 pp 83% evidence | 15.5/25 ROCE 27% · OPM 18% 76% evidence | 8.8/20 P/E 118× · PEG — 15% evidence | 14.9/20 RS sector 5.7% · RS bench 43% · 1Y 61.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 23.7 + 15.5 + 8.8 + 14.9 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Saksoft LtdSAKSOFT | 62.8/100Mixed-positive evidence90% evidence | TURNING | 24.0/35 Revenue 14% · PAT 22% · OPM change 3 pp 88% evidence | 18.7/25 ROCE 25.5% · OPM 18% 100% evidence | 13.5/20 P/E 16.4× · PEG 0.41 100% evidence | 6.6/20 RS sector -21.2% · RS bench -3.3% · 1Y -21.8%6 of 11 weeks ahead 70% evidence |
| Exact sum: 24 + 18.7 + 13.5 + 6.6 = 62.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -21.2% and the one-year return is -21.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Softtech Engineers LtdSOFTTECH | 61.2/100Mixed-positive evidence76% evidence | FADING | 27.8/35 Revenue 39.5% · PAT 100% · OPM change 6.2 pp 83% evidence | 11.7/25 ROCE 6.2% · OPM 21.4% 95% evidence | 8.8/20 P/E 117× · PEG — 15% evidence | 12.9/20 RS sector 12.7% · RS bench 15.9% · 1Y 15.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 27.8 + 11.7 + 8.8 + 12.9 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Datamatics Global Services LtdDATAMATICS | 60.9/100Mixed-positive evidence90% evidence | TURNING | 20.9/35 Revenue 15.3% · PAT -5.8% · OPM change 6 pp 88% evidence | 17.9/25 ROCE 20.8% · OPM 21% 100% evidence | 8.5/20 P/E 20.6× · PEG 1.08 100% evidence | 13.6/20 RS sector 9.6% · RS bench 0.6% · 1Y -5.4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 17.9 + 8.5 + 13.6 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14R Systems International LtdRSYSTEMS | 60.4/100Mixed-positive evidence96% evidence | BASING | 23.9/35 Revenue 18.3% · PAT 48.3% · OPM change 2 pp 88% evidence | 14.5/25 ROCE 19.5% · OPM 18% 100% evidence | 18.2/20 P/E 13.5× · PEG 0.26 100% evidence | 3.8/20 RS sector -26% · RS bench -24.4% · 1Y -37.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 14.5 + 18.2 + 3.8 = 60.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26% and the one-year return is -37.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15BLS E-Services LtdBLSE | 58.2/100Mixed-positive evidence71% evidence | LEADER | 19.4/35 Revenue 100% · PAT 16.9% · OPM change -2 pp 83% evidence | 10.5/25 ROCE 17% · OPM 6% 76% evidence | 9.0/20 P/E 47.5× · PEG — 15% evidence | 19.3/20 RS sector 47.6% · RS bench 51.9% · 1Y 62.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 10.5 + 9 + 19.3 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16String Metaverse Ltd534535 | 56.8/100Mixed-positive evidence78% evidence | ASLEEP | 26.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 83% evidence | 15.4/25 ROCE 41.6% · OPM 10% 76% evidence | 14.7/20 P/E 6.8× · PEG — 50% evidence | 0.4/20 RS sector -67.5% · RS bench -60.8% · 1Y -80.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.4 + 14.7 + 0.4 = 56.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -67.5% and the one-year return is -80.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 17Sonata Software LtdSONATSOFTW | 56.7/100Mixed-positive evidence93% evidence | BREAKING OUT | 11.7/35 Revenue 5.4% · PAT 8.9% · OPM change 1 pp 83% evidence | 16.8/25 ROCE 30.7% · OPM 8% 95% evidence | 14.4/20 P/E 17.7× · PEG 0.61 100% evidence | 13.8/20 RS sector -1.1% · RS bench 1.3% · 1Y -21.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 16.8 + 14.4 + 13.8 = 56.7 · Decision use: Price leads the evidence: RS versus the benchmark is 1.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Ksolves India LtdKSOLVES | 56.6/100Mixed-positive evidence87% evidence | ASLEEP | 17.6/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.3/25 ROCE 131% · OPM 30.3% 95% evidence | 13.6/20 P/E 18× · PEG — 50% evidence | 5.1/20 RS sector -10% · RS bench -7.2% · 1Y -15.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 20.3 + 13.6 + 5.1 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Infosys LtdINFY | 56.1/100Mixed-positive evidence82% evidence | BASING | 18.2/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.0/25 ROCE 40% · OPM 24% 76% evidence | 14.1/20 P/E 14.7× · PEG — 50% evidence | 3.8/20 RS sector -21.2% · RS bench -18.8% · 1Y -25.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 20 + 14.1 + 3.8 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Xchanging Solutions LtdXCHANGING | 55.0/100Mixed-positive evidence77% evidence | ASLEEP | 21.0/35 Revenue 9.7% · PAT 18% · OPM change 3 pp 83% evidence | 15.3/25 ROCE 18% · OPM 37% 95% evidence | 13.4/20 P/E 12.4× · PEG — 50% evidence | 5.3/20 RS sector -24.4% · RS bench -11.9% · 1Y -27.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 15.3 + 13.4 + 5.3 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21RNIT AI Solutions LtdAUTOPALIND | 54.4/100Thin evidence · provisional51% evidence | 20.5/35 Revenue 59.8% · PAT 66.7% · OPM change 5.1 pp 83% evidence | 14.6/25 ROCE 20.2% · OPM 40.2% 76% evidence | 9.3/20 P/E 39.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 10 weeks ahead 0% evidence | |
| Exact sum: 20.5 + 14.6 + 9.3 + 10 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Dynacons Systems & Solutions LtdDSSL | 53.7/100Mixed-positive evidence83% evidence | LEADER | 15.7/35 Revenue 12.4% · PAT 19.4% · OPM change 0 pp 83% evidence | 16.8/25 ROCE 29.8% · OPM 9% 95% evidence | 7.8/20 P/E 18.5× · PEG — 50% evidence | 13.4/20 RS sector 10.4% · RS bench 14.3% · 1Y 19.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 16.8 + 7.8 + 13.4 = 53.7 · Decision use: Price leads the evidence: RS versus the benchmark is 14.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 23HCL Technologies LtdHCLTECH | 53.5/100Mixed-positive evidence76% evidence | TURNING | 12.6/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.0/25 ROCE 30.4% · OPM 20% 76% evidence | 9.5/20 P/E 20.2× · PEG — 50% evidence | 12.4/20 RS sector 9.9% · RS bench -6.4% · 1Y -9.6%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 9.5 + 12.4 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Tanla Platforms LtdTANLA | 53.2/100Mixed-positive evidence94% evidence | TURNING | 14.4/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.4/25 ROCE 26.3% · OPM 16% 100% evidence | 13.1/20 P/E 14.6× · PEG 1.21 100% evidence | 9.3/20 RS sector -12% · RS bench 5.2% · 1Y -9.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 16.4 + 13.1 + 9.3 = 53.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 25AvenuesAI LtdCCAVENUE | 52.8/100Mixed-positive evidence83% evidence | TURNING | 20.5/35 Revenue 100% · PAT 25.5% · OPM change -2.3 pp 88% evidence | 8.2/25 ROCE 7.7% · OPM 3.7% 100% evidence | 14.9/20 P/E 19.6× · PEG 0.37 65% evidence | 9.2/20 RS sector -2.2% · RS bench -3.6% · 1Y -1.2%5 of 11 weeks ahead 70% evidence |
| Exact sum: 20.5 + 8.2 + 14.9 + 9.2 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Seshaasai Technologies LtdSTYL | 52.8/100Mixed-positive evidence73% evidence | TURNING | 13.1/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 16.9/25 ROCE 27.7% · OPM 23% 100% evidence | 12.8/20 P/E 21.2× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 13.1 + 16.9 + 12.8 + 10 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Tata Consultancy Services LtdTCS | 52.5/100Mixed-positive evidence94% evidence | ASLEEP | 11.1/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.3/25 ROCE 63% · OPM 26% 100% evidence | 11.8/20 P/E 15.9× · PEG 1.85 100% evidence | 7.3/20 RS sector -4.6% · RS bench -15.1% · 1Y -24.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.1 + 22.3 + 11.8 + 7.3 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Expleo Solutions LtdEXPLEOSOL | 51.4/100Mixed-positive evidence77% evidence | ASLEEP | 15.4/35 Revenue 8.1% · PAT 20.4% · OPM change -1 pp 83% evidence | 15.7/25 ROCE 24.8% · OPM 15% 95% evidence | 13.9/20 P/E 9.2× · PEG — 50% evidence | 6.4/20 RS sector -13.4% · RS bench -13.1% · 1Y -34.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 15.7 + 13.9 + 6.4 = 51.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29IZMO LtdIZMO | 51.2/100Mixed-positive evidence77% evidence | TURNING | 16.2/35 Revenue 26.1% · PAT -2% · OPM change -5 pp 83% evidence | 12.5/25 ROCE 12.6% · OPM 14% 95% evidence | 6.6/20 P/E 31.2× · PEG — 50% evidence | 15.9/20 RS sector 28.9% · RS bench 19.5% · 1Y 161%7 of 10 weeks ahead 70% evidence |
| Exact sum: 16.2 + 12.5 + 6.6 + 15.9 = 51.2 · Decision use: Price leads the evidence: RS versus the benchmark is 19.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 30LTM LtdLTM | 50.8/100Mixed-positive evidence100% evidence | TURNING | 17.1/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.8/25 ROCE 29.6% · OPM 18% 100% evidence | 11.2/20 P/E 23.1× · PEG 1.18 100% evidence | 4.7/20 RS sector -16% · RS bench -13.6% · 1Y -14.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.8 + 11.2 + 4.7 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Wipro LtdWIPRO | 50.3/100Mixed-positive evidence94% evidence | ASLEEP | 13.8/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 14.9/25 ROCE 17.8% · OPM 19% 100% evidence | 13.2/20 P/E 13.8× · PEG 1.4 100% evidence | 8.4/20 RS sector -1.9% · RS bench -18.5% · 1Y -29.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.8 + 14.9 + 13.2 + 8.4 = 50.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 32Mastek LtdMASTEK | 50.3/100Mixed-positive evidence82% evidence | TURNING | 14.1/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.8/25 ROCE 18% · OPM 15% 76% evidence | 12.7/20 P/E 13.2× · PEG — 50% evidence | 9.7/20 RS sector -6.7% · RS bench -4.4% · 1Y -24.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 13.8 + 12.7 + 9.7 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Subex LtdSUBEXLTD | 50.0/100Thin evidence · provisional53% evidence | TURNING | 19.8/35 Revenue -2.3% · PAT 100% · OPM change 31 pp 62% evidence | 8.7/25 ROCE 12.8% · OPM 12.6% 95% evidence | 9.9/20 P/E 21.7× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 8.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 19.8 + 8.7 + 9.9 + 11.6 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Birlasoft LtdBSOFT | 49.4/100Mixed-negative evidence100% evidence | BASING | 19.8/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.0/25 ROCE 21.2% · OPM 16% 100% evidence | 14.5/20 P/E 14.2× · PEG 0.62 100% evidence | 2.1/20 RS sector -21.6% · RS bench -19% · 1Y -23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 13 + 14.5 + 2.1 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Blue Cloud Softech Solutions Ltd539607 | 49.1/100Mixed-negative evidence65% evidence | TURNING | 20.3/35 Revenue 25.7% · PAT 39.5% · OPM change 8 pp 83% evidence | 10.7/25 ROCE 14.2% · OPM 17% 76% evidence | 9.6/20 P/E 29.8× · PEG — 15% evidence | 8.5/20 RS sector -1.9% · RS bench -14.9% · 1Y -35.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 10.7 + 9.6 + 8.5 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Hexaware Technologies LtdHEXT | 48.3/100Mixed-negative evidence94% evidence | TURNING | 14.5/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.5/25 ROCE 30.1% · OPM 16% 100% evidence | 10.4/20 P/E 24.2× · PEG 0.81 100% evidence | 5.9/20 RS sector -21.4% · RS bench -9.9% · 1Y -24%6 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 17.5 + 10.4 + 5.9 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Mphasis LtdMPHASIS | 48.1/100Mixed-negative evidence94% evidence | TURNING | 15.3/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.1/25 ROCE 22.1% · OPM 18% 100% evidence | 5.6/20 P/E 23.1× · PEG 2.19 100% evidence | 10.1/20 RS sector 0% · RS bench -9.2% · 1Y -10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.3 + 17.1 + 5.6 + 10.1 = 48.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 38Zensar Technologies LtdZENSARTECH | 47.4/100Mixed-negative evidence100% evidence | BASING | 15.8/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.8/25 ROCE 22.8% · OPM 15% 100% evidence | 13.3/20 P/E 14.5× · PEG 1.11 100% evidence | 4.5/20 RS sector -23.7% · RS bench -21.9% · 1Y -36.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13.8 + 13.3 + 4.5 = 47.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39TechNVision Ventures LtdTECHNVISN | 46.5/100Mixed-negative evidence62% evidence | ASLEEP | 17.0/35 Revenue 18.2% · PAT 90.9% · OPM change -5.7 pp 62% evidence | 8.9/25 ROCE 12.9% · OPM -4.1% 95% evidence | 8.5/20 P/E 12760× · PEG — 15% evidence | 12.1/20 RS sector 32.1% · RS bench -21.9% · 1Y 16.2%0 of 7 weeks ahead 70% evidence |
| Exact sum: 17 + 8.9 + 8.5 + 12.1 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40XT Global Infotech LtdXTGLOBAL | 46.5/100Mixed-negative evidence61% evidence | 18.7/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.2/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.4/20 P/E 40.8× · PEG — 50% evidence | 9.2/20 RS sector -1.1% · RS bench -12.7% · 1Y -18.7%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.7 + 9.2 + 9.4 + 9.2 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Unicommerce eSolutions LtdUNIECOM | 46.4/100Mixed-negative evidence70% evidence | ASLEEP | 14.9/35 Revenue 51.6% · PAT 16.1% · OPM change -4.8 pp 83% evidence | 17.1/25 ROCE 21.1% · OPM 13.4% 95% evidence | 9.1/20 P/E 46.5× · PEG — 15% evidence | 5.3/20 RS sector -14.5% · RS bench -24.2% · 1Y -31.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.9 + 17.1 + 9.1 + 5.3 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42Capillary Technologies India LtdCAPILLARY | 44.2/100Thin evidence · provisional59% evidence | ASLEEP | 21.6/35 Revenue 22.5% · PAT 271.4% · OPM change -2 pp 88% evidence | 4.0/25 ROCE 3.6% · OPM 16% 100% evidence | 8.6/20 P/E 134× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 21.6 + 4 + 8.6 + 10 = 44.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Magellanic Cloud LtdMCLOUD | 44.0/100Mixed-negative evidence77% evidence | TURNING | 13.3/35 Revenue 17.1% · PAT 11.7% · OPM change -3 pp 83% evidence | 15.4/25 ROCE 19.8% · OPM 26% 95% evidence | 11.9/20 P/E 14.9× · PEG — 50% evidence | 3.4/20 RS sector -54.5% · RS bench -27.4% · 1Y -64.9%5 of 11 weeks ahead 70% evidence |
| Exact sum: 13.3 + 15.4 + 11.9 + 3.4 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Mindteck (India) LtdMINDTECK | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 14.6/35 Revenue -4% · PAT 10.3% · OPM change 2 pp 83% evidence | 10.6/25 ROCE 15.1% · OPM 10% 95% evidence | 11.7/20 P/E 18.2× · PEG — 50% evidence | 6.9/20 RS sector -10.1% · RS bench -9.9% · 1Y -6.9%3 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 10.6 + 11.7 + 6.9 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 45Innovana Thinklabs LtdINNOVANA | 38.7/100Mixed-negative evidence77% evidence | ASLEEP | 10.2/35 Revenue 27.9% · PAT -18.2% · OPM change -46.5 pp 83% evidence | 10.0/25 ROCE 16.4% · OPM 9.7% 95% evidence | 9.7/20 P/E 17.8× · PEG — 50% evidence | 8.8/20 RS sector -0.4% · RS bench -22% · 1Y -39.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.2 + 10 + 9.7 + 8.8 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4663 Moons Technologies Ltd63MOONS | 38.7/100Mixed-negative evidence62% evidence | TURNING | 16.7/35 Revenue 100% · PAT -17% · OPM change 397 pp 83% evidence | 3.4/25 ROCE -3.7% · OPM -57% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.6/20 RS sector -22.4% · RS bench 26.5% · 1Y -10.7%7 of 11 weeks ahead 70% evidence |
| Exact sum: 16.7 + 3.4 + 10 + 8.6 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 47Allied Digital Services LtdADSL | 38.2/100Mixed-negative evidence62% evidence | ASLEEP | 18.1/35 Revenue 19.9% · PAT 25.8% · OPM change 0.8 pp 62% evidence | 5.5/25 ROCE 7.3% · OPM -3.8% 95% evidence | 10.4/20 P/E 18.1× · PEG — 15% evidence | 4.2/20 RS sector -29.8% · RS bench -19.6% · 1Y -33.4%5 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 5.5 + 10.4 + 4.2 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Kellton Tech Solutions LtdKELLTONTEC | 36.4/100Mixed-negative evidence81% evidence | ASLEEP | 10.4/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.5/25 ROCE 15% · OPM 11% 95% evidence | 11.5/20 P/E 8.3× · PEG — 50% evidence | 5.0/20 RS sector -18.8% · RS bench -25.3% · 1Y -55.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 10.4 + 9.5 + 11.5 + 5 = 36.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 49Aurionpro Solutions LtdAURIONPRO | 35.9/100Mixed-negative evidence93% evidence | ASLEEP | 13.5/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.7/25 ROCE 16.3% · OPM 17% 100% evidence | 9.9/20 P/E 19.3× · PEG 1.39 65% evidence | 1.8/20 RS sector -29.5% · RS bench -27.8% · 1Y -47.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 10.7 + 9.9 + 1.8 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Moschip Technologies LtdMOSCHIP | 30.3/100Adverse evidence87% evidence | TURNING | 8.1/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 6.8/25 ROCE 11% · OPM 8.2% 100% evidence | 3.7/20 P/E 127× · PEG 5.04 65% evidence | 11.7/20 RS sector 1.9% · RS bench -2.2% · 1Y 23.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 6.8 + 3.7 + 11.7 = 30.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Quick Heal Technologies LtdQUICKHEAL | 20.4/100Adverse evidence69% evidence | ASLEEP | 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.6/25 ROCE -4.7% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.6/20 RS sector -35.1% · RS bench -34% · 1Y -52.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 6.2 + 1.6 + 10 + 2.6 = 20.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Covance Softsol Ltd544361 | 66.7/100Thin evidence · provisional49% evidence | 25.7/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.9/25 ROCE 31.4% · OPM 23.1% 76% evidence | 10.7/20 P/E 15.3× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 82.1% · 1Y — 25% evidence | |
| Exact sum: 25.7 + 17.9 + 10.7 + 12.4 = 66.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Meta Infotech LtdMETA | 54.6/100Thin evidence · provisional21% evidence | 17.1/35 Revenue — · PAT — · OPM change -2 pp 10% evidence | 16.3/25 ROCE 51.1% · OPM 8% 57% evidence | 11.2/20 P/E 13× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -52.4%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 17.1 + 16.3 + 11.2 + 10 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54TAC Infosec LtdTAC | 54.2/100Thin evidence · provisional50% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change -6 pp 26% evidence | 20.5/25 ROCE 38.1% · OPM 45% 95% evidence | 9.1/20 P/E 46.4× · PEG — 15% evidence | 6.5/20 RS sector -13.2% · RS bench -13.4% · 1Y 12.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 20.5 + 9.1 + 6.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Exato Technologies Ltdthis page544626 | 52.7/100Thin evidence · provisional33% evidence | 17.1/35 Revenue — · PAT — · OPM change -3.9 pp 32% evidence | 16.1/25 ROCE 26.8% · OPM 10.4% 76% evidence | 9.5/20 P/E 36.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17.1 + 16.1 + 9.5 + 10 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56Unified Data- Tech Solutions LtdUNIFIED | 52.4/100Thin evidence · provisional22% evidence | 15.8/35 Revenue — · PAT — · OPM change -8 pp 15% evidence | 16.9/25 ROCE 47.9% · OPM 13% 57% evidence | 9.7/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 9.4%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 15.8 + 16.9 + 9.7 + 10 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Kody Technolab LtdKODYTECH | 52.3/100Thin evidence · provisional48% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 12.8/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 121× · PEG — 15% evidence | 15.6/20 RS sector 10.3% · RS bench 66.8% · 1Y 94.4%7 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 12.8 + 8.7 + 15.6 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Trident Techlabs LtdTECHLABS | 46.5/100Thin evidence · provisional40% evidence | 16.2/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.2/25 ROCE 26.7% · OPM 27% 71% evidence | 10.8/20 P/E 14.9× · PEG — 15% evidence | 3.3/20 RS sector -50.3% · RS bench -56.5% · 1Y -65.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16.2 + 16.2 + 10.8 + 3.3 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Excelsoft Technologies LtdEXCELSOFT | 46.3/100Thin evidence · provisional43% evidence | ASLEEP | 12.8/35 Revenue — · PAT — · OPM change -11 pp 45% evidence | 13.3/25 ROCE 13.6% · OPM 30% 95% evidence | 10.2/20 P/E 19.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 12.8 + 13.3 + 10.2 + 10 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60ERP Soft Systems Ltd530909 | 44.8/100Thin evidence · provisional41% evidence | 20.3/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.9/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -56.7%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 20.3 + 8 + 8.9 + 7.6 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61Veefin Solutions LtdVEEFIN | 43.3/100Thin evidence · provisional33% evidence | 17.0/35 Revenue — · PAT — · OPM change -12.4 pp 5% evidence | 10.4/25 ROCE 6.8% · OPM 20% 57% evidence | 9.3/20 P/E 40.5× · PEG — 15% evidence | 6.6/20 RS sector -7.2% · RS bench -18.7% · 1Y -30.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17 + 10.4 + 9.3 + 6.6 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62IDream Film Infrastructure Company Ltd504375 | 41.0/100Thin evidence · provisional30% evidence | 13.5/35 Revenue — · PAT 0% · OPM change — 29% evidence | 5.0/25 ROCE -9.2% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 144.4% · 1Y —4 of 4 weeks ahead 25% evidence | |
| Exact sum: 13.5 + 5 + 10 + 12.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63Orient Technologies LtdORIENTTECH | 33.7/100Thin evidence · provisional45% evidence | ASLEEP | 15.6/35 Revenue — · PAT — · OPM change -5 pp 13% evidence | 2.2/25 ROCE 8.4% · OPM 2.4% 95% evidence | 9.0/20 P/E 47.7× · PEG — 15% evidence | 6.9/20 RS sector -7.1% · RS bench -16.1% · 1Y -11.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.2 + 9 + 6.9 = 33.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Exato Technologies Ltd's share price today?
Exato Technologies Ltd trades at ₹586. The company is valued at ₹589 Cr. The stock sits at 100% of its 52-week range of ₹354–₹586, +54.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 33 weeks in. — as of 31 July 2026.
What were Exato Technologies Ltd's latest quarterly results?
Exato Technologies Ltd reported revenue of ₹61.1 Cr and net profit of ₹4.2 Cr for the Mar 26 quarter. Revenue rose 4.0% and profit fell 24.2% year on year. Earnings per share were ₹4.21. The operating margin was 10.4%, 3.9 pp lower than a year earlier. — as of 31 July 2026.
What is Exato Technologies Ltd's revenue?
Exato Technologies Ltd reported revenue of ₹61.1 Cr in the Mar 26 quarter, +4.0% year on year. For the full FY26 fiscal year, revenue was ₹168 Cr (+35.5%). Over the last 3 years revenue compounded at 32.0% a year. — as of 31 July 2026.
What is Exato Technologies Ltd's profit?
Exato Technologies Ltd earned ₹4.2 Cr of net profit in the Mar 26 quarter, −24.2% year on year. Full-year FY26 profit was ₹16.0 Cr. The operating margin ran 10.4% in the latest quarter. — as of 31 July 2026.
What is Exato Technologies Ltd's market cap?
Exato Technologies Ltd's market capitalisation is ₹589 Cr at a share price of ₹586. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Exato Technologies Ltd's P/E ratio?
Exato Technologies Ltd trades at a P/E of 36.6×, at the 98th percentile of its own 1-year range, against a long-run median of 0.1×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Exato Technologies Ltd pay a dividend?
No — Exato Technologies Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Exato Technologies Ltd overvalued?
On its own history, Exato Technologies Ltd looks expensive against its own history: its P/E of 36.6× sits at the 98th percentile of its 1-year range (long-run median 0.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Exato Technologies Ltd growing?
Not right now — Exato Technologies Ltd's latest numbers are shrinking: latest-quarter revenue +4.0% year on year, profit −24.2%, and the margin −3.9 pp at 10.4%. The 3-year compound rates are 32.0% (revenue) and 47.4% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Exato Technologies Ltd performing?
Exato Technologies Ltd is in a confirmed uptrend, 33 weeks in. Its latest quarter's revenue rose 4.0% and profit fell 24.2% year on year. This describes what the data did, not a rating. — as of 31 July 2026.
Is Exato Technologies Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 33 of stage 2), trading +54.9% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Will Exato Technologies Ltd's share price go up?
This page publishes no price forecast for Exato Technologies Ltd. What it measures instead: the share price is ₹586, the price is in a confirmed uptrend 33 weeks in. Its P/E of 36.6× sits at the 98th percentile of its own 1-year range. — as of 31 July 2026.
Who owns Exato Technologies Ltd?
Promoters hold 54.7% of Exato Technologies Ltd, foreign institutions 0.0%, domestic institutions 7.9% and the public 37.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Exato Technologies Ltd have too much debt?
No — Exato Technologies Ltd's debt-to-equity is 0.24, and operating profit covers the interest bill 12×. FY26 borrowings were ₹21.0 Cr against equity of ₹88.0 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Exato Technologies Ltd's capex?
Exato Technologies Ltd spent ₹32.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹13.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Exato Technologies Ltd's cash flow?
Exato Technologies Ltd generated ₹2.0 Cr of operating cash flow in FY26 and ₹−11.0 Cr of free cash flow after ₹13.0 Cr of capital spending. Reported profit that year was ₹16.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Exato Technologies Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 3% of Exato Technologies Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹2.0 Cr against reported profit of ₹16.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is Exato Technologies Ltd in its business cycle?
Exato Technologies Ltd's FY26 operating margin was 14.0%, against a 4-year band of 7.0%–14.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 10.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Exato Technologies Ltd story?
Biggest watch item: the P/E sits at the 98th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Exato Technologies Ltd a stock worth studying right now?
This is not investment advice. The machine read: Exato Technologies Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.